76. 下垂体性ゴナドトロピン分泌亢進症 Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details
臨床試験数 : 29 / 薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05341115 (ClinicalTrials.gov) | March 20, 2023 | 18/4/2022 | A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP) | Central Precocious Puberty | Drug: Leuprorelin Acetate Depot 3M | Takeda | NULL | Not yet recruiting | N/A | 9 Years | All | 80 | Phase 4 | China |
| 2 | NCT03963752 (ClinicalTrials.gov) | August 15, 2019 | 22/5/2019 | Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine | Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine | Idiopathic Precocious Puberty | Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg Injection | Children's Hospital of Fudan University | NULL | Recruiting | 5 Years | 8 Years | Female | 164 | Phase 4 | China |
| 3 | NCT03695237 (ClinicalTrials.gov) | October 24, 2018 | 2/10/2018 | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) | A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP) | Central Precocious Puberty (CPP) | Drug: Leuprolide Acetate (LA) | AbbVie | NULL | Active, not recruiting | 2 Years | 11 Years | All | 45 | Phase 3 | United States;Puerto Rico |
| 4 | NCT02993926 (ClinicalTrials.gov) | June 24, 2017 | 13/12/2016 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants | An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty | Central Precocious Puberty | Drug: Enantone;Drug: GnRH agonist | Takeda | NULL | Completed | N/A | N/A | All | 108 | China | |
| 5 | NCT02974270 (ClinicalTrials.gov) | June 2016 | 19/5/2016 | Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate | Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate | Precocious Puberty, Central | Drug: Leuprolide | Kyungpook National University | NULL | Recruiting | N/A | 9 Years | Both | 100 | Phase 4 | Korea, Republic of |
| 6 | NCT02811471 (ClinicalTrials.gov) | June 2016 | 21/6/2016 | Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and B | Central Precocious Puberty | Drug: Leuprolide | Nemours Children's Clinic | Tolmar Inc. | Recruiting | 2 Years | 9 Years | Both | 5 | Phase 3 | United States |
| 7 | NCT02452931 (ClinicalTrials.gov) | August 31, 2015 | 5/5/2015 | Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty | Precocious Puberty, Central | Drug: Leuprolide Acetate 45 mg | Tolmar Inc. | NULL | Completed | 2 Years | 9 Years | All | 64 | Phase 3 | United States;Argentina;Canada;Chile;Mexico;New Zealand |
| 8 | NCT02427958 (ClinicalTrials.gov) | August 7, 2015 | 23/4/2015 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants | An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty | Central Precocious Puberty | Drug: Leuprorelin | Takeda | NULL | Completed | 1 Year | 9 Years | All | 307 | Phase 4 | China |
| 9 | NCT03316482 (ClinicalTrials.gov) | June 11, 2015 | 12/10/2017 | Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty | A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty | Central Precocious Puberty | Drug: Leuplin DPS 11.25mg | Jin Soon Hwang | NULL | Completed | 4 Years | 9 Years | All | 58 | Phase 4 | Korea, Republic of |
| 10 | NCT02920515 (ClinicalTrials.gov) | September 2012 | 16/8/2016 | Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty | Multi-site Study of Comprehensive Treatment for Children Precocious Puberty | Central Precocious Puberty | Drug: Triptorlin or Leuprorelin;Drug: Zhibo dihuang pills;Drug: Dabu ying pills | Ruijin Hospital | Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital | Completed | 2 Years | 14 Years | Female | 740 | Phase 4 | NULL |
| 11 | NCT01634321 (ClinicalTrials.gov) | July 2011 | 3/7/2012 | The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty | The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study | Central Precocious Puberty | Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | Daewoong Pharmaceutical Co. LTD. | NULL | Completed | 4 Years | 9 Years | Both | 63 | Phase 4 | Korea, Republic of |
| 12 | NCT00667446 (ClinicalTrials.gov) | December 2008 | 24/4/2008 | Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty | Precocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious Puberty | Drug: Leuprolide Acetate 3 Month Depot | AbbVie (prior sponsor, Abbott) | NULL | Completed | N/A | N/A | All | 72 | Phase 3 | United States;Puerto Rico |
| 13 | NCT00635817 (ClinicalTrials.gov) | June 2008 | 7/3/2008 | A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty | Puberty, Precocious | Drug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mg | Abbott | NULL | Completed | 2 Years | 11 Years | All | 84 | Phase 3 | United States;Puerto Rico |
| 14 | NCT00438217 (ClinicalTrials.gov) | May 2006 | 21/2/2007 | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Central Precocious Puberty | Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists) | University of Pisa | NULL | Recruiting | 1 Year | 18 Years | Both | 100 | Phase 4 | Italy |
| 15 | NCT00660010 (ClinicalTrials.gov) | January 1991 | 15/4/2008 | Study of Lupron Depot In The Treatment of Central Precocious Puberty | Study of Lupron Depot In The Treatment of Central Precocious Puberty | Puberty, Precocious | Drug: Lupron (leuprolide acetate) | Abbott | NULL | Completed | N/A | 10 Years | All | 55 | Phase 3 | United States |
| 16 | EUCTR2014-004494-16-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product’ INN or Proposed INN: LEUPRORELIN ACETATE | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 72 | United States;Puerto Rico | ||||
| 17 | EUCTR2014-004495-36-Outside-EU/EEA (EUCTR) | 28/11/2014 | A study of Lupron Depot Lupron Depot in treatment of central premature puberty | Study of Lupron Depot in the Treatment of Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 55 | United States | ||||
| 18 | EUCTR2014-004493-42-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulationsin Children with Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product Product Name: Leuprolide acetate depot INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 80 | Phase 3 | United States;Puerto Rico |